GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celldex Therapeutics Inc (NAS:CLDX) » Definitions » Degree of Operating Leverage

CLDX (Celldex Therapeutics) Degree of Operating Leverage : 1.82 (As of Mar. 2025)


View and export this data going back to 1990. Start your Free Trial

What is Celldex Therapeutics Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. Celldex Therapeutics's Degree of Operating Leverage for the quarter that ended in Mar. 2025 was 1.82. The higher Degree of Operating Leverage, the higher operating risk the company will take.

The industry rank for Celldex Therapeutics's Degree of Operating Leverage or its related term are showing as below:

CLDX's Degree of Operating Leverage is ranked worse than
74.97% of 887 companies
in the Biotechnology industry
Industry Median: -0.03 vs CLDX: 1.82

Celldex Therapeutics Degree of Operating Leverage Historical Data

The historical data trend for Celldex Therapeutics's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celldex Therapeutics Degree of Operating Leverage Chart

Celldex Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.08 -1.06 -1.11 0.17 18.76

Celldex Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.32 0.22 0.23 18.76 1.82

Competitive Comparison of Celldex Therapeutics's Degree of Operating Leverage

For the Biotechnology subindustry, Celldex Therapeutics's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celldex Therapeutics's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celldex Therapeutics's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where Celldex Therapeutics's Degree of Operating Leverage falls into.


;
;

Celldex Therapeutics Degree of Operating Leverage Calculation

Celldex Therapeutics's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -217.209 (Mar. 2025) / -150.179 (Mar. 2024) - 1 )/( 7.559 (Mar. 2025) / 6.072 (Mar. 2024) - 1 )
=0.4463/0.2449
=1.82***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Celldex Therapeutics  (NAS:CLDX) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


Celldex Therapeutics Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of Celldex Therapeutics's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Celldex Therapeutics Business Description

Traded in Other Exchanges
Address
53 Frontage Road, Suite 220, Perryville III Building, Hampton, NJ, USA, 08827
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
Executives
Anthony S Marucci director, officer: President and CEO 66 COLD HILL DRIVE, MENDAHM NJ 07945
Samuel Bates Martin officer: SVP and CFO C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Elizabeth Crowley officer: SVP, Chief Product Dev Officer C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Diane C. Young officer: SVP, Chief Medical Officer 175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103
Freddy A. Jimenez officer: SVP & General Counsel C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Margo Heath-chiozzi officer: SVP of of Regulatory Affairs C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Richard M. Wright officer: Sr. VP & CCO C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Sarah Cavanaugh officer: SVP of Corp. Affairs & Admin. C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Garry Arthur Neil director 555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Cheryl Cohen director C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105
Rita Jain director C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Tibor Keler officer: Sen. VP & Ch Scientific Off. 30 PARK ROAD, OTTSVILLE PA 18942
James J Marino director C/O ONCONOVA THERAPEUTICS, 375 PHEASANT RUN, NEWTOWN PA 18940
Keith L Brownlie director 777 OLD SAW MILL RIVER RD, TARRYTOWN NY 10591
Gerald Phd Mcmahon director 300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114